



Trend of OPDIVO

Sales Trend of OPDIVO by Each Cancer




Number of Patients Newly Prescribed with OPDIVO by Each Cancer (Estimation)



Source: Estimation from external and internal data


Trend of total sales of ICPIs and OPDIVO share



Source: External data


Number of GC* Patients per year in Japan

* : Unresectable Advanced or Recurrent GC



Estimation based on internal survey (2020)

Prescription Ratio in Patients Newly Treated* for 1L GC




*Patients starting treatment within the last 3 month

Source: External data (Nov 2021~Feb 2024: n=200~204)


Number of ESC* Patients per year in Japan

* : Unresectable Advanced or Recurrent ESC



Estimation based on internal survey (2022)


Prescription Ratio in Patients Newly Treated* for 1L ESC(Squamous Cell Carcinoma)



*Patients starting treatment within the last 3 month


Source: External data (May 2022~Jan 2024: n=150~155)

Number of ESC(Perioperative)Patients per year in Japan



Estimation based on internal survey (2022)

Prescription Ratio in Patients Newly Treated* for ESC(adjuvant chemotherapy)



*Patients starting treatment within the last 3 months

Source: External data (Mar 2022~Mar 2024 n=130~152)

Number of NSCLC* Patients per year in Japan

* Unresectable Advanced or Recurrent NSCLC



NSCLC 58,000/Year

**Non-Squamous (NSQ)
43,500**

**Squamous (SQ)
14,500**

**With Mutation
23,000**

**Without Mutation
20,500**

**NSQ-MT
23,000**

**NSQ-WT + SQ
35,000**

1L

**EGFR / ALK / ROS /
BRAF Inhibitor**

**Opdivo + Yervoy + Chemo (All Comers)
Opdivo + Yervoy (All Comers)
Opdivo + Chemo (PD-L1<1%)**

Approved Nov. 2020


Opdivo + Bevacizumab + Chemo

Revision of labeling Jun. 2021

IO Mono / IO + Chemo

IO + Chemo

Prescription Ratio in Patients Newly Treated* for 1L NSCLC




(Before approval)

*Patients starting treatment within the last 1 month (Except Driver Mutation)


Source: External data (Nov 2020~Mar 2024: n=167~245)

Number of Bladder Cancer(Perioperative)Patients per year in Japan



Estimation based on internal survey (2022)

Prescription Ratio in Patients Newly Treated* for Bladder Cancer(adjuvant chemotherapy)




*Patients starting treatment within the last 3 months

Source: External data (Jan 2022~Nov 2023: n=200)


Number of RCC* Patients per year in Japan

* : Unresectable or Metastatic RCC



Estimation based on internal survey (2022)

Prescription Ratio in Patients Newly Treated* for 1L RCC



*Patients starting treatment within the last 3 months

Source: External data (Sep 2018~Dec 2023: n=46~150)